Embecta Corp. engages in the provision of medical devices used in the treatment of diabetes. The company is headquartered in Parsippany, New Jersey and currently employs 1,850 full-time employees. The company went IPO on 2022-03-21. The firm has a portfolio of marketed products, including a variety of pen needles, syringes and safety injection devices. Its pen needles are sterile, single-use, medical devices, designed to be used in conjunction with pen injectors that inject insulin or other diabetes medications. The company also sells safety pen needles, which have shields on both ends of the cannula that automatically deploy after the injection to help prevent needlestick exposure and injury during injection and disposal. Its traditional and safety pen needles are compatible and frequently used with pen injectors in the market. The company sells sterile, single-use insulin syringes, which are used to inject insulin drawn from insulin vials. The company also sells safety insulin syringes. The company distributes its products through a variety of channels, including retail, hospitals and pharmacies.
P/E (price / listing EPS) Forward revenue growth (NTM) 
